EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer

Shengbai Xue, Haiyan Xu, Jingyu Ma, Yanling Wang, Wenxin Lu, Jiujie Cui, Liwei Wang

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Shengbai Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Department of Medical Oncology, Renji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong Un…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms, Drug Resistance, Neoplasm, Unfolded Protein Response. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, School of Medicine, Shanghai Jiao Tong University, CSCO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive, with KRAS mutations, particularly KRAS G12D, present in the majority of cases. While development of KRAS G12D inhibitors is rapid, acquired resistance remains a major clinical challenge. Therefore, in this study, we aimed to evaluate the efficacy of novel KRAS G12D inhibitor HRS-4642, investigate its potential resistance mechanisms, and overcome resistance through combination therapy. The results demonstrated that although HRS-4642 showed potent and selective anti-tumor activity, acquired resistance has been observed in a clinical trial (NCT06520488). Through integrated analyses in vitro (HRS-4642-resistant cell lines), in vivo (HRS-4642-resistant patient-derived xenograft (PDX)), and in clinical samples (HRS-4642-resistant patients from NCT06520488), we identified reactivation of the unfolded protein response (UPR) via the MEK/ERK pathway as a key resistance mechanism. To overcome this, we performed a comprehensive drug combination screen and found that nimotuzumab synergized strongly with HRS-4642. This combination effectively enhanced efficacy and reversed resistance both in vitro and in vivo (cell-derived xenograft (CDX) and PDX). Mechanistically, while the addition of nimotuzumab was validated both in vitro and in vivo to sustain the suppression of the MEK/ERK/UPR axis, it concurrently exacerbated endoplasmic reticulum stress in vitro, thereby driving profound cellular damage. Our findings not only reveal a clinically relevant resistance mechanism to KRAS G12D inhibition but also provide a rational, effective combined strategy. Ultimately, the combination of HRS-4642 with nimotuzumab offers a promising therapeutic strategy for PDAC patients harboring KRAS G12D mutations, laying a foundation for advancing clinical research in overcoming resistance to KRAS G12D-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Pancreatic NeoplasmsDrug Resistance, NeoplasmUnfolded Protein ResponseCarcinoma, Pancreatic DuctalAntibodies, Monoclonal, HumanizedHumansAnimalsXenograft Model Antitumor AssaysCell Line, TumorMiceMAP Kinase Signaling SystemAntineoplastic Combined Chemotherapy ProtocolsMutationFemale

Stichwörter der Autor:innen

Acquired resistanceKRAS G12DPancreatic ductal adenocarcinomaTargeted therapyUnfold protein response

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Department of Medical Oncology, Renji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • State Key Laboratory of Systems Medicine for Cancer, Department of Medical Oncology, Renji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: uhai…
  • State Key Laboratory of Systems Medicine for Cancer, Department of Medical Oncology, Renji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: cuij…
  • State Key Laboratory of Systems Medicine for Cancer, Department of Medical Oncology, Renji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory…

Förderung

  • National Natural Science Foundation of China
  • School of Medicine, Shanghai Jiao Tong University
  • CSCO

Zitieren

APA

Xue, S., Xu, H., Ma, J., Wang, Y., Lu, W., Cui, J., & Wang, L. (2026). Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218684

Vancouver

Xue S, Xu H, Ma J, Wang Y, Lu W, Cui J, et al. Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218684

BibTeX
@article{Xue2026,
  author = {Xue, Shengbai and Xu, Haiyan and Ma, Jingyu and Wang, Yanling and Lu, Wenxin and Cui, Jiujie and Wang, Liwei},
  title = {Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218684}
}
Kostenlos starten →